Transcatheter Arterial Embolization Using Imipenem/Cilastatin Sodium for Chronic Low Back Pain Resistant to Conservative Treatment: A Pilot Study with 2-Year Follow-Up

Fujiwara, Keishi; Inui, Shigeru; Shibuya, Masabumi; Sugihara, Eiji; Miyazaki, Koichi; Sakugawa, Takayuki; Okuno, Yuji

doi:10.1007/s00270-021-02976-1

Cited by 10 publications

(4 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another study on the safety of proximal embolization using an IPM/CS mixture in humans was conducted to treat tendinopathy and enthesopathy (Okuno et al 2013;Fujiwara et al 2021). The study revealed that even when IPM/CS was injected from the proximal point of the branches feeding the target site, no complications associated with IPM/CS embolization occurred.…”

Section: Discussionmentioning

confidence: 99%

Transcatheter arterial embolization for acute lower gastrointestinal bleeding using imipenem/cilastatin: A single-center retrospective study

Hiraki

Sato

Osugi

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Transcatheter arterial embolization (TAE) is a standard treatment for acute lower gastrointestinal bleeding (LGIB) in situations where endoscopic approaches are impossible or ineffective. Various embolic materials, such as metallic coils and N-butyl cyanoacrylate, are used. This study aimed to evaluate the clinical outcomes of an imipenem/cilastatin (IPM/CS) mixture as an embolic agent in TAE for acute LGIB. Results: Twelve patients (mean age, 67 years) with LGIB treated with TAE using IPM/CS were retrospectively evaluated between February 2014 and September 2022. All patients showed evidence of extravasation on computed tomography and 50% (6/12) also showed evidence on angiography. The technical success rate for TAE in this study was 100%, including in patients who showed active extravasation on angiography. The clinical success rate was 83.3% (10/12), with two patients experiencing re-bleeding within 24 h after the procedure. No ischemic complications were observed and no bleeding episodes or other complications were reported during the follow-up period. Conclusions: This study revealed that using IPM/CS as an embolic agent in TAE for acute LGIB may be safe and effective, even in cases of active bleeding.

show abstract

Section: Discussionmentioning

confidence: 99%

Transcatheter arterial embolization for acute lower gastrointestinal bleeding using imipenem/cilastatin: A single-center retrospective study

Hiraki

Sato

Osugi

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…IPM/CS has been shown to possess several unique characteristics, including the production of particles predominantly <60 µm in size, a relatively short embolic effect of <48 hours, and its effectiveness in embolizing small blood vessels but not large vessels, making it a useful embolic agent [5 , 6] . It has also been safely used for proximal embolization in the human intestine and in the treatment of tendinopathy and enthesopathy [7] , [8] – 9 , 11] . Few safety reports also describe the use of IPM/CS for treating small bowel bleeding [10 , 11] .…”

Section: Discussionmentioning

confidence: 99%

Successful treatment of multiple microbleeds in a large area of the small bowel by transcatheter arterial embolization using imipenem/cilastatin as embolization material

Hiraki

Sato

Okada

et al. 2023

Radiology Case Reports

View full text Add to dashboard Cite

“…In einer Kohorte mit 14 Patienten führte die TAPE zu einer signifikanten Beschwerdebesserung und damit zum klinischen Erfolg bei 79 % und 57 % der Patienten nach 3 bzw. 24 Monaten [34]. Trotz der noch jungen Therapie sind die Ergebnisse, die mit den aktuellen Materialien und Methoden erzielt werden, aber durchaus vielversprechend und ermutigend, insbesondere dann, wenn man die verzweifelte Situation vieler Patienten mit chronischen Gelenkschmerzen und deren Therapiemöglichkeiten bedenkt.…”

Section: Weitere Indikationenunclassified

“…In einer Kohorte mit 14 Patienten führte die TAPE zu einer signifikanten Beschwerdebesserung und damit zum klinischen Erfolg bei 79% und 57% der Patienten nach 3 bzw. 24 Monaten 34 .…”

Section: Klinische Einsatzmöglichkeitenunclassified

Transarterielle periartikuläre Embolisation (TAPE): klinischer Einsatz und aktuelle Entwicklungen

Freyhardt,

Katoh

2023

Radiologie up2date

View full text Add to dashboard Cite

ZusammenfassungObwohl bei der transarteriellen periartikulären Embolisation (TAPE) noch viele Aspekte erforscht werden müssen, findet sie eine zunehmende Verbreitung und Akzeptanz bei der Behandlung von Gelenkschmerzen. Diese Arbeit stellt den aktuellen Stand vor, benennt mögliche Indikationen, beschreibt die interventionelle Technik und fasst die in der Literatur verfügbaren Ergebnisse zusammen.

show abstract

Transcatheter Arterial Embolization Using Imipenem/Cilastatin Sodium for Chronic Low Back Pain Resistant to Conservative Treatment: A Pilot Study with 2-Year Follow-Up

Cited by 10 publications

References 21 publications

Transcatheter arterial embolization for acute lower gastrointestinal bleeding using imipenem/cilastatin: A single-center retrospective study

Transcatheter arterial embolization for acute lower gastrointestinal bleeding using imipenem/cilastatin: A single-center retrospective study

Successful treatment of multiple microbleeds in a large area of the small bowel by transcatheter arterial embolization using imipenem/cilastatin as embolization material

Transarterielle periartikuläre Embolisation (TAPE): klinischer Einsatz und aktuelle Entwicklungen

Contact Info

Product

Resources

About